Tandem Diabetes (TNDM) Care announced the publication of a study in the American Diabetes Association’s Diabetes Care journal. The study, a sub-analysis from the 2IQP trial, found that the Control-IQ+ automated insulin delivery system was beneficial for adults with insulin-treated type 2 diabetes, regardless of C-peptide levels. The analysis showed participants in the AID group experienced a mean HbA1c decrease of 0.8% from baseline, which was significantly greater than the control group, and this improvement was consistent between high and low C-peptide groups.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold Rating
- Tandem Diabetes assumed with an Outperform at Oppenheimer
- Tandem announces Health Canada authorization for t:slim mobile application
- Tandem Diabetes price target raised to $11 from $10.35 at Citi
- Tandem Diabetes Care: Strategic Growth Potential and Market Expansion Drive Buy Rating